Yi Han

Yi Han


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 February 2023 in Microorganisms
Verified
Journal Article
Open access
PDF file
YGYaqiong Guo
Yaqiong Guo
WYWenjie Yuan
Wenjie Yuan
NLNa Lyu
Na Lyu
YPYuanlong Pan
Yuanlong Pan
XCXiaoqing Cao
Xiaoqing Cao
BZBaoli Zhu
Baoli Zhu
Lung adenocarcinoma (LADC) is a prevalent type of lung cancer that is associated with lung and gut microbiota. However, the interactions between these microbiota and cancer development remain unclear. In this study, a microbiome study was performed on paired fecal and bronchoalveolar lavage fluid (BALF) samples from 42 patients with LADC and 64 healthy controls using 16S rRNA gene amplicon and shotgun metagenome sequencing, aiming to correlate the lung and gut microbiota with LADC. Patients with LADC had reduced α-diversity in the gut microbiome and altered β-diversity compared with healthy controls, and the abundances of Flavonifractor, Eggerthella, and Clostridium were higher in the gut microbiome of LADC patients. The increased abundance of microbial species, such as Flavonifractor plautii, was associated with advanced-stage LADC and a higher metastasis rate. Phylogenetically, Haemophilus parainfluenzae was the most frequently shared taxon in the lung and gut microbiota of LADC patients. Gut microbiome functional pathways involving leucine, propanoate, and fatty acids were associated with LADC progression. In conclusion, the low diversity of the gut microbiota and the presence of H. parainfluenzae in gut and lung microbiota were linked to LADC development, while an increased abundance of F. plautii and the enriched metabolic pathways could be associated with the progression of LADC.

24 November 2021 in Frontiers in Cell and Developmental Biology
Verified
Journal Article
Open access
HLHefei Li
Hefei Li
YZYushan Zhang
Yushan Zhang
XLXiaomei Lan
Xiaomei Lan
JYJianhua Yu
Jianhua Yu
CYChangshuang Yang
Changshuang Yang
DYDaping Yu
Daping Yu
Lung cancer is the leading cause of cancer death worldwide. Cisplatin is the major DNA-damaging anticancer drug that cross-links the DNA in cancer cells, but many patients inevitably develop resistance with treatment. Identification of a cisplatin sensitizer might postpone or even reverse the development of cisplatin resistance. Halofuginone (HF), a natural small molecule isolated from Dichroa febrifuga, has been found to play an antitumor role. In this study, we found that HF inhibited the proliferation, induced G0/G1 phase arrest, and promoted apoptosis in lung cancer cells in a dose-dependent manner. To explore the underlying mechanism of this antitumor effect of halofuginone, we performed RNA sequencing to profile transcriptomes of NSCLC cells treated with or without halofuginone. Gene expression profiling and KEGG analysis indicated that PI3K/AKT and MAPK signaling pathways were top-ranked pathways affected by halofuginone. Moreover, combination of cisplatin and HF revealed that HF could sensitize the cisplatin-resistant patient-derived lung cancer organoids and lung cancer cells to cisplatin treatment. Taken together, this study identified HF as a cisplatin sensitizer and a dual pathway inhibitor, which might provide a new strategy to improve prognosis of patients with cisplatin-resistant lung cancer.

1 February 2025 in Cancer Immunology, Immunotherapy
Verified
Journal Article
Open access
PDF file
SSShishengnan Song
Shishengnan Song
CWChong Wang
Chong Wang
YCYangchao Chen
Yangchao Chen
XZXIAORONG ZHOU
XIAORONG ZHOU
YHYi Han
Yi Han
HZHaijian Zhang
Haijian Zhang
The amazing diversity of B cells within the tumor microenvironment is the basis for the diverse development of B cell-based immunotherapies. Here, we focus on elucidating the mechanisms of tumor intervention mediated by four tumor-infiltrating B lymphocytes. Naive B cells present the initial antigen, germinal center B cell subsets enhance antibody affinity, and immunoglobulin subtypes exert multiple immune effects, while regulatory B cells establish immune tolerance. Together they reflect the complexity of the changing dynamics of cancer immunity. Additionally, we have investigated the dynamic effects of tumor-infiltrating B lymphocytes in immunotherapy and their relationship to prognosis, providing new insights into potential treatment strategies for patients.

21 March 2022 in European Journal of Surgical Oncology
Verified
Journal Article
Closed access
XYXian Ye
Xian Ye
YLYang Liu
Yang Liu
JYJunling Yang
Junling Yang
YWYan Wang
Yan Wang
XCXiaohong Cui
Xiaohong Cui
HZHaijian Zhang
Haijian Zhang

13 February 2023 in Journal of Cancer Research and Clinical Oncology
Verified
Journal Article
Closed access
PDF file
NXNing Xiao
Ning Xiao
XCXiaoqing Cao
Xiaoqing Cao
ZLZhidong Liu
Zhidong Liu
YHYi Han
Yi Han

11 October 2025 in Translational Oncology
Verified
Journal Article
Open access
YLYang Liu
Yang Liu
YLYixia Li
Yixia Li
XZXiaotian Zhai
Xiaotian Zhai
LYLei Yang
Lei Yang
JLJie Li
Jie Li
YHYi Han
Yi Han
Previous studies have demonstrated that the overexpression of circadian rhythm-related gene basic helix-loop-helix ARNT like 2 (BMAL2) promotes the progression of malignant tumors. However, its downstream targets remain largely unclear. The aim of the present study was to explore the significance of BMAL2/mitochondrial ribosomal protein L15 (MRPL15) in non-small cell lung cancer (NSCLC). We found that BMAL2 was upregulated in NSCLC tissues, as compared with normal tissues. NSCLC patients with late stage exhibited a high expression of BMAL2. In vitro, BMAL2 overexpression promoted the growth of NSCLC cells. Mechanistically, BMAL2 potentiated the expression of MRPL15 at the mRNA and protein levels. Luciferase reporter and chromatin immunoprecipitation (ChIP)-qPCR results showed that BMAL2 enhanced the transcription activity of the MRPL15 gene by binding to its promoter. MRPL15 upregulation accelerated the cell cycle progression of NSCLC cells. Ferroptosis and apoptosis were clearly inhibited by MRPL15. BMAL2 overexpression promoted the tumorigenesis ability of NSCLC cells, which was suppressed by MRPL15 knockdown. The induction of ferroptosis and apoptosis completely reversed the oncogenic function of BMAL2 following MRPL15 knockdown. In addition, there was a positive correlation between BMAL2 and MRPL15 in patients with NSCLC. BMAL2 or MRPL15 overexpression was associated with poor prognosis NSCLC. In conclusion, the present findings demonstrated that BMAL2 exhibited a tumor promoting effect in NSCLC through the regulation of MRPL15-mediated cell cycle procession, apoptosis and ferroptosis. The induction of apoptosis and ferroptosis are a promising strategy for the treatment of NSCLC patients with a high BMAL2 expression.